Dr. Vinay Prasad, head of the FDA's vaccines and biologics division, is stepping down at the end of April after a controversial year overseeing approvals for vaccines, gene therapies, and biotech products.
UBS starts coverage on ALX Oncology (ALXO) with a Buy rating and $6 price target, highlighting the potential of its CD47 blocker evorpacept in metastatic breast cancer.
GoodRx partners with Eli Lilly to help employers subsidize Zepbound KwikPen at a $449 monthly price. The new Employer Direct program reduces out-of-pocket costs for workers without overhauling health benefits.
French pharma leader Servier acquires U.S. biotech Day One in a $2.5B cash deal to become #1 in pediatric low-grade glioma and expand rare cancer treatments for children and adults. Expected close: Q2 2026.
Nutex Health shares plunged after Q4 profit fell to $11.8M, due to a $55M one-time arbitration claim true-up. Revenue missed estimates, but the company announced a $25M stock buyback.
Barclays downgrades PacBio to Underweight from Equal Weight, cuts price target to $1.50 citing competition and H1 2026 consumables slowdown ahead of SPRQ-Nx launch.
